Israel Englander’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $73.1M | Buy |
1,525,000
+663,400
| +77% | +$28.5M | 0.03% | 667 |
|
|
2026
Q1 | $31.7M | Buy |
861,600
+218,300
| +34% | +$10.3M | 0.01% | 1183 |
|
|
2025
Q4 | $32.7M | Sell |
643,300
-466,700
| -42% | -$23.9M | 0.01% | 1112 |
|
|
2025
Q3 | $61.6M | Buy |
1,110,000
+496,600
| +81% | +$29.1M | 0.03% | 722 |
|
|
2025
Q2 | $42.3M | Buy |
613,400
+610,100
| +18,488% | +$41.5M | 0.02% | 922 |
|
|
2025
Q1 | $229K | Sell |
3,300
-394,500
| -99% | -$32.6M | ﹤0.01% | 5239 |
|
|
2024
Q4 | $34.2M | Buy |
397,800
+232,200
| +140% | +$25.1M | 0.02% | 1068 |
|
|
2024
Q3 | $19.7M | Buy |
165,600
+60,900
| +58% | +$8.12M | 0.01% | 1563 |
|
|
2024
Q2 | $14.9M | Buy |
104,700
+16,500
| +19% | +$2.19M | 0.01% | 1741 |
|
|
2024
Q1 | $11.3M | Sell |
88,200
-111,800
| -56% | -$13.3M | ﹤0.01% | 2071 |
|
|
2023
Q4 | $20.7M | Sell |
200,000
-46,000
| -19% | -$4.55M | 0.01% | 1515 |
|
|
2023
Q3 | $22.4M | Sell |
246,000
-174,000
| -41% | -$15.3M | 0.01% | 1345 |
|
|
2023
Q2 | $34M | Buy |
420,000
+120,000
| +40% | +$9.8M | 0.02% | 990 |
|
|
2023
Q1 | $23.9M | Buy |
+300,000
| New | +$21.3M | 0.01% | 1212 |
|
|
2022
Q4 | – | Sell |
-300,000
| Closed | -$14.9M | – | 6894 |
|
|
2022
Q3 | $14.9M | Buy |
300,000
+280,000
| +1,400% | +$15M | 0.01% | 1655 |
|
|
2022
Q2 | $1.11M | Sell |
20,000
-980,000
| -98% | -$54.4M | ﹤0.01% | 4263 |
|
|
2022
Q1 | $55.5M | Buy |
+1,000,000
| New | +$51.3M | 0.03% | 622 |
|
|
2021
Q4 | – | Sell |
-400,000
| Closed | -$19.2M | – | 7194 |
|
|
2021
Q3 | $19.2M | Hold |
400,000
| – | – | 0.01% | 1371 |
|
|
2021
Q2 | $16.8M | Buy |
+400,000
| New | +$15.5M | 0.01% | 1364 |
|
|
2020
Q3 | – | Sell |
-700,000
| Closed | -$22.9M | – | 4712 |
|
|
2020
Q2 | $22.9M | Buy |
+700,000
| New | +$22.3M | 0.03% | 659 |
|
|
2020
Q1 | – | Sell |
-800,000
| Closed | -$23.2M | – | 4284 |
|
|
2019
Q4 | $23.2M | Sell |
800,000
-100,000
| -11% | -$2.77M | 0.03% | 757 |
|
|
2019
Q3 | $23.3M | Buy |
900,000
+440,400
| +96% | +$11.1M | 0.04% | 682 |
|
|
2019
Q2 | $11.7M | Sell |
459,600
-202,200
| -31% | -$5M | 0.02% | 1134 |
|
|
2019
Q1 | $17.3M | Sell |
661,800
-338,200
| -34% | -$8.31M | 0.03% | 895 |
|
|
2018
Q4 | $23M | Hold |
1,000,000
| – | – | 0.04% | 646 |
|
|
2018
Q3 | $23.6M | Buy |
1,000,000
+608,200
| +155% | +$14.8M | 0.03% | 754 |
|
|
2018
Q2 | $9.04M | Buy |
+391,800
| New | +$9.31M | 0.01% | 1392 |
|
|
2018
Q1 | – | Sell |
-400,000
| Closed | -$10.7M | – | 3947 |
|
|
2017
Q4 | $10.7M | Buy |
+400,000
| New | +$10.2M | 0.01% | 1287 |
|
|
2016
Q2 | – | Sell |
-400,000
| Closed | -$10.8M | – | 3439 |
|
|
2016
Q1 | $10.8M | Sell |
400,000
-128,400
| -24% | -$3.44M | 0.03% | 784 |
|
|
2015
Q4 | $15.3M | Buy |
+528,400
| New | +$14.6M | 0.03% | 683 |
|
Other funds holding NVO
F
Israel Englander's NVO Position: Q2 2026 in Review
Israel Englander increased its Novo Nordisk (NVO) stake by 45% in Q2 2026, buying an estimated $26.9M and bringing the position to 2,035,939 shares worth $97.6M. The position accounts for 0.04% of the portfolio, ranked #523.
Israel Englander first reported a position in NVO in Q2 2013 and has held it in 47 quarters since. The position peaked at $309M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Israel Englander held 2,035,939 shares of Novo Nordisk worth $97.6M as of Q2 2026.
- Israel Englander bought 627,086 Novo Nordisk shares in Q2 2026, an estimated $26.9M.
- Novo Nordisk made up 0.04% of Israel Englander's portfolio in Q2 2026, its #523 holding.
- Israel Englander first reported a position in Novo Nordisk in Q2 2013 and has held it in 47 quarters since.
- Israel Englander's Novo Nordisk position peaked at $309M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.